The CESTAT held that insulin products manufactured using...

The CESTAT held that insulin products manufactured using recombinant DNA technology would qualify as 'mono-component insulin' and are entitled to exemption under Notification No. 12/2012 Customs dated March 17, 2012, as they are lifesaving drugs. The classification of the imported insulin products is based on their content rather than source. The Tribunal accepted that 'mono-component' refers to the purity of insulin rather than its source, and there was no evidence that the disputed products had impurity levels higher than 1 PPM. The CESTAT upheld the classification of the imported insulin products under chapter heading 3004 31 10, making them eligible for the exemption as lifesaving drugs.

View Source

Login to TaxTMI

Username/Email Address

Password

Remember Me (auto-login)

By checking this you will be auto logged in, if required, for next 3 days (unless manually logged out)

Log In

Forgot Password ?

The CESTAT held that insulin products manufactured using...

The Email Id has not been verified. Click on the link we have sent on

Go Back Done

Didn't receive the mail? Resend Mail

Don't have an account? Register Here